McKesson (NYSE:MCK) updated its FY21 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $13.95-14.75 for the period, compared to the Thomson Reuters consensus estimate of $15.48. The company issued revenue guidance of +2-4% to $218.6-222.9 billion, compared to the consensus revenue estimate of $234.49 billion.McKesson also updated its FY 2021
Pre-Market guidance to 13.95-14.75 EPS.
MCK stock opened at $149.42 on Friday. McKesson has a 52 week low of $112.60 and a 52 week high of $172.18. The company has a market capitalization of $25.80 billion, a PE ratio of 29.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.82. The company’s 50-day simple moving average is $136.14 and its 200 day simple moving average is $142.81. The company has a debt-to-equity ratio of 1.51, a quick ratio of 0.56 and a current ratio of 0.99.
McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $4.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.10 by $0.17. McKesson had a net margin of 0.39% and a return on equity of 41.07%. The firm had revenue of $58.54 billion during the quarter, compared to the consensus estimate of $55.60 billion. During the same quarter in the previous year, the firm posted $3.69 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts forecast that McKesson will post 15.01 EPS for the current year.
Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on McKesson from $186.00 to $187.00 and gave the company an overweight rating in a report on Wednesday, March 18th. TheStreet upgraded McKesson from a c rating to a b rating in a research report on Wednesday. Cowen upped their price objective on shares of McKesson from $174.00 to $186.00 and gave the stock an outperform rating in a research report on Thursday. Guggenheim raised shares of McKesson from a neutral rating to a buy rating in a report on Friday, March 13th. Finally, Goldman Sachs Group upgraded shares of McKesson from a neutral rating to a buy rating and boosted their target price for the company from $173.00 to $174.00 in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. McKesson currently has a consensus rating of Buy and an average target price of $168.50.
In related news, CEO Brian S. Tyler sold 4,063 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $135.00, for a total transaction of $548,505.00. Following the completion of the transaction, the chief executive officer now directly owns 16,255 shares in the company, valued at approximately $2,194,425. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 8,187 shares of company stock worth $1,064,057. 0.88% of the stock is currently owned by corporate insiders.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Story: What is a Buy-Side Analyst?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.